First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
Fibrosis is a normal process for repairing injured tissue. However, aberrant or hyperfibrotic responses result in serious pathologic conditions and sometimes life-threatening diseases. A new class of drugs antagonizing type 1 lysophosphatidic acid receptor has been developed and is under investigation in clinical trials for the treatment of idiopathic pulmonary fibrosis and systemic fibrosis or scleroderma. This will be the first drug in its class to target G-protein-coupled receptors for lysophosphatidic acid.